BioSpace News Archive

Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology’s ASCO20 Virtual Scientific Program from May 29-31.

Pharmaceutical Executive®, a multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, is proud to announce the honorees of the 2020 Emerging Pharma Leaders awards program

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced that Chief Executive Officer Alistair Macdonald and Chief Financial Officer Jason Meggs are scheduled to present at the UBS Virtual Global Healthcare Conference on Tuesday, May 19, 2020, at 9:10 a.m. ET.

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that Executive Chairman Robert J. Coury and President Rajiv Malik will present at the 2020 RBC Capital Markets’ Virtual Global Healthcare Conference on Tuesday, May 19, 2020 at 8 a.m. ET.

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and unaudited financial results for the quarter ended March 31, 2020 and also provided a corporate update.

Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 study of PTR-01 (BridgeBio designation BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB).

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2020 and provides a business update.

Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced that it will release its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, May 14, 2020.

The U.S. Food and Drug Administration continued to take action in the ongoing response effort to the COVID-19 pandemic